This is a working overview of Lactam bridge, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
== Career == Upon receiving his Ph.D., Gattuso moved to Australia where he was a postdoctoral researcher at the Australian Institute of Marine Science(1988-1990). In 1990, Gattuso took a position of CNRS research scientist at Centre de Biologie et Écologie Tropicale et Méditerranéenne of the University of Perpignan (1990-1992). He then moved to the Scientific Center of Monaco to launch and lead the Ecophysiology and Biogeochemistry group. In 1998, Gattuso went back to a CNRS joint laboratory at the Villefranche Oceanographic Observatory and moved to the ranks of Research Professor (directeur de recherche). He is also Associate Scientist at the Institute for Sustainable Development and International Relations (IDDRI-SciencesPo, Paris). Gattuso has been visiting professor or scientist at Rutgers University, the National Center for Atmospheric Research and Shantou University. Gattuso is the founding editor-in-chief of Biogeosciences and served or has served in the editorial board of several scientific journals. He founded the Biogeosciences Division of the European Geosciences Union, and has received multiple awards and honors for his research contributions. He led the launch of the Ocean Acidification International Coordination Centre at the International Atomic Energy Agency, co-edited the first book on ocean acidification (Oxford University Press) and contributed to several IPCC products (5th Assessment Report, Special Report on 1.5°C of Warming, and the Special Report on the Ocean and Cryosphere in a Changing Climate).
Aromatic polyimides are synthesized by the reaction of dianhydrides with diamines, such as pyromellitic anhydride with p-phenylenediamine. It can also be accomplished using diisocyanates in place of diamines. Solubility considerations sometimes suggest use of the half acid-half ester of the dianhydride, instead of the dianhydride itself. Polymerization is accomplished by a two-stage process due to the insolubility of polyimides. The first stage forms a soluble and fusible high-molecular-weight poly(amic acid) in a polar aprotic solvent such as NMP or N,N-dimethylacetamide. The poly(amic aicd) can then be processed into the desired physical form of the final polymer product (e.g., film, fiber, laminate, coating) which is insoluble and infusible.
ACT-389949: A small-molecule FPR2 agonist that has completed phase 1 clinical trials BMS-986235: Another FPR2 agonist in phase 1 trials, with evidence of resolving cardiac inflammation and improving cardiac function in preclinical models. BLXA4 (Methyl ester-benzo-lipoxin A4): An LXA4 analog tested in phase 1 clinical trials for gingival inflammation, shown to reduce local inflammation. Rezuforimod is a potent and selective FPR2 agonist that inhibits neutrophil adhesion and exhibits broad anti-inflammatory activity.
== Education == Nuzzo graduated from the University of South Florida with a bachelor's degree in industrial engineering and went on to obtain her Ph.D in statistics from Stanford University in 2004, supervised by Richard A. Olshen. Her dissertation was written on the usage of stochastic models in biochemistry. Nuzzo also graduated from the University of California Santa Cruz's science writing program.
== Management == BACM may be alarming to parents and lead to unnecessary extensive tests. Treatment consists of oral analgesics, rest, and adequate hydration. Hospitalization is usually not necessary. Full recovery can be expected within a week, however, recurrences can occur.
Sources: en.wikipedia.org
Bolognia, Jean L.; et al. (2007). Dermatology. St. Louis: Mosby. ISBN 978-1-4160-2999-1. James, William D.; et al. (2006). Andrews' Diseases of the Skin: Clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
Le continued developing patches for the game until the release of Counter-Strike 1.0, after which he stepped away from the main title and began work on a prototype for Counter-Strike 2. However, after nearly three years of development, the project was shelved when it was only about 25% complete. With Counter-Strike 2 discontinued, Minh Le turned his attention to developing Day of Defeat: Source. Following its release, he left Valve in 2006 to pursue an independent project. After spending two years working with a small team on the project, he moved to South Korea in 2008 to work with the company named FIX Korea, which provided funding for its continued development. Le's new game was later revealed to be Tactical Intervention, a game similar in style to Counter-Strike created with a modified version of Valve's Source engine. In October 2013, Minh Le joined Facepunch Studios, where he worked on Rust. He remained at the studio until February 2018, when he departed to join Pearl Abyss the following month. There, he worked on MMOFPS game called PLAN 8. Le left Pearl Abyss in 2023. Minh Le later continued working in small-team and independent game development. His later projects included Alpha Response, a tactical PvE shooter released in early access. In 2026, Le said he had considered returning to work on Counter-Strike 2, particularly on weapon animations and maps, while also stating that he believed Counter-Strike was "in a really good space".
==== Determination by genetics or the environment ==== Behaviors can be either innate or learned from the environment, or both, dependent on the organism. The more complex nervous systems (or brains) are, the more influence learning has on behavior. However, even in mammals, a large fraction of behavior is genetically determined. For instance, prairie voles tend to be monogamous, while meadow voles are more promiscuous, a difference that is strongly determined by a single gene, Avpr1a, encoding a receptor for the peptide hormone Vasopressin.
Variants encoded by alternative exons were reported in human and mouse corin. A variant allele (T555I/Q568P) was found in African Americans with hypertension and cardiac hypertrophy. The amino acid substitutions impaired corin activity. An insertion variant in exon 1 alters the cytoplasmic tail. This variant appeared more frequently in hypertensive patients. CORIN mutations were found in patients with hypertension. In the cat family (Felidae), mutant alleles of the corin gene are responsible for "golden" or "metallic" fur, in particular the "sunshine" coloration (FIFé EMS Code "u") of the Siberian Forest Cat breed, but also in the British Shorthair and some other domestic cats (where EMS Code "y" is used to denote this coloration), as well as in golden tigers.
When the breast-filler fat is injected to the breasts in clumps (too-large measures), fat cells emplaced too distant from blood vessels might die, which can lead to fat tissue necrosis, causing lumps, calcifications, and the eventual formation of liponecrotic cysts.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.